Y D'Souza1, S Dowlatshahi, B M Bennett. 1. Department of Pharmacology and Toxicology, Faculty of Health Sciences, Queen's University, Kingston, Ontario, Canada.
Abstract
BACKGROUND AND PURPOSE: Recent studies have suggested an essential role for aldehyde dehydrogenase 2 (ALDH2) in the bioactivation of organic nitrates such as glyceryl trinitrate (GTN). In the present study, we utilized an in vivo GTN tolerance model to further investigate the role of ALDH2 in GTN bioactivation and tolerance. EXPERIMENTAL APPROACH: We assessed changes in aortic ALDH activity, and in ALDH2 protein expression in various rat blood vessels (aorta, vena cava, femoral artery and femoral vein) during continuous GTN exposure (0.4 mg·h⁻¹ for 6, 12, 24 or 48 h) or after a 1-, 3- or 5-day drug-free period following a 48 h exposure to GTN, in relation to changes in vasodilator responses to GTN and in vascular GTN biotransformation. KEY RESULTS: A decrease was observed in both ALDH2 protein expression (80% in tolerant veins and 30% in tolerant arteries after 48 h exposure to GTN) and aortic ALDH activity, concomitant with decreased vasodilator responses to GTN and decreased aortic GTN biotransformation. However, after a 24 h drug-free period following 48 h of GTN exposure, vasodilator responses to GTN and aortic GTN biotransformation activity had returned to control values, whereas vascular ALDH2 expression and aortic ALDH activity were still significantly depressed, and remained so for 3-5 days following cessation of GTN exposure. CONCLUSIONS AND IMPLICATIONS: The dissociation of reduced ALDH activity and ALDH2 expression from the duration of the impaired vasodilator and biotransformation responses to GTN in nitrate-tolerant blood vessels, suggests that factors other than changes in ALDH2-mediated GTN bioactivation contribute to nitrate tolerance.
BACKGROUND AND PURPOSE: Recent studies have suggested an essential role for aldehyde dehydrogenase 2 (ALDH2) in the bioactivation of organic nitrates such as glyceryl trinitrate (GTN). In the present study, we utilized an in vivo GTN tolerance model to further investigate the role of ALDH2 in GTN bioactivation and tolerance. EXPERIMENTAL APPROACH: We assessed changes in aortic ALDH activity, and in ALDH2 protein expression in various rat blood vessels (aorta, vena cava, femoral artery and femoral vein) during continuous GTN exposure (0.4 mg·h⁻¹ for 6, 12, 24 or 48 h) or after a 1-, 3- or 5-day drug-free period following a 48 h exposure to GTN, in relation to changes in vasodilator responses to GTN and in vascular GTN biotransformation. KEY RESULTS: A decrease was observed in both ALDH2 protein expression (80% in tolerant veins and 30% in tolerant arteries after 48 h exposure to GTN) and aortic ALDH activity, concomitant with decreased vasodilator responses to GTN and decreased aortic GTN biotransformation. However, after a 24 h drug-free period following 48 h of GTN exposure, vasodilator responses to GTN and aortic GTN biotransformation activity had returned to control values, whereas vascular ALDH2 expression and aortic ALDH activity were still significantly depressed, and remained so for 3-5 days following cessation of GTN exposure. CONCLUSIONS AND IMPLICATIONS: The dissociation of reduced ALDH activity and ALDH2 expression from the duration of the impaired vasodilator and biotransformation responses to GTN in nitrate-tolerant blood vessels, suggests that factors other than changes in ALDH2-mediated GTN bioactivation contribute to nitrate tolerance.
Authors: Andrei L Kleschyov; Matthias Oelze; Andreas Daiber; Yale Huang; Hanke Mollnau; Eberhard Schulz; Karsten Sydow; Birgit Fichtlscherer; Alexander Mülsch; Thomas Münzel Journal: Circ Res Date: 2003-10-09 Impact factor: 17.367
Authors: Ivan S de la Lande; Jacqueline M Stepien; Andrew C Philpott; Patrick A Hughes; Irene Stafford; John D Horowitz Journal: Eur J Pharmacol Date: 2004-08-02 Impact factor: 4.432
Authors: Karsten Sydow; Andreas Daiber; Matthias Oelze; Zhiqiang Chen; Michael August; Maria Wendt; Volker Ullrich; Alexander Mülsch; Eberhard Schulz; John F Keaney; Jonathan S Stamler; Thomas Münzel Journal: J Clin Invest Date: 2004-02 Impact factor: 14.808
Authors: Matteo Beretta; Karl Gruber; Alexander Kollau; Michael Russwurm; Doris Koesling; Walter Goessler; Wing Ming Keung; Kurt Schmidt; Bernd Mayer Journal: J Biol Chem Date: 2008-05-01 Impact factor: 5.157
Authors: Bruce A Berkowitz; Jacob Lenning; Nikita Khetarpal; Catherine Tran; Johnny Y Wu; Ali M Berri; Kristin Dernay; E Mark Haacke; Fatema Shafie-Khorassani; Robert H Podolsky; John C Gant; Shaniya Maimaiti; Olivier Thibault; Geoffrey G Murphy; Brian M Bennett; Robin Roberts Journal: FASEB J Date: 2017-06-07 Impact factor: 5.191
Authors: Abdul R Maher; Sayqa Arif; Melanie Madhani; Khalid Abozguia; Ibrar Ahmed; Bernadette O Fernandez; Martin Feelisch; A G O'Sullivan; Arthur Christopoulos; Aaron L Sverdlov; Doan Ngo; Rustem Dautov; Philip E James; John D Horowitz; Michael P Frenneaux Journal: Br J Pharmacol Date: 2013-06 Impact factor: 8.739
Authors: Sayqa Arif; Alessandra Borgognone; Erica Lai-Sze Lin; Aine G O'Sullivan; Vishal Sharma; Nigel E Drury; Ashvini Menon; Peter Nightingale; Jorge Mascaro; Robert S Bonser; John D Horowitz; Martin Feelisch; Michael P Frenneaux; Melanie Madhani Journal: Br J Pharmacol Date: 2015-04-29 Impact factor: 8.739
Authors: G Wölkart; M Beretta; M V Wenzl; H Stessel; K Schmidt; N Maeda; B Mayer; A Schrammel Journal: Br J Pharmacol Date: 2013-04 Impact factor: 8.739